New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
11:22 EDTTLM, OREX, BGOptions with increasing implied volatility: OREX TLM IP BG
News For OREX;TLM;BG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
08:22 EDTBGBunge volatility at low end of historic range as shares near six-year high
Bunge overall option implied volatility of 17 compares to its 26-week average of 19 according to Track Data, suggesting decreasing price movement.
November 21, 2014
09:17 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTTLMTalisman Energy, Ecopetrol announce discovery in Block CPO-9, Colombia
Talisman Energy (TLM) affiliate Talisman Oil & Gas and Ecopetrol S.A. (ECP) have proven the presence of hydrocarbons in the Nueva Esperanza-1 exploratory well, located in block CPO-9, Department of Meta, Colombia. The Nueva Esperanza-1 well was spudded on July 18, 2014 and reached total depth at 12,056 feet on September 26, 2014. During an initial 8-day flow test using an electro submersible pumping system, 309 feet of perforations in the T2 formation stabilized at a daily flow rate of 910 barrels of 8 degrees API crude oil with less than 2% water cut during the last day of flow. Talisman and Ecopetrol are jointly analyzing the results and will file an application with the Colombian authorities to place the Nueva Esperanza-1 well on long-term test. Approval has been granted to drill two down-dip appraisal wells, the first of which, Nueva Esperanza-2, started drilling operations on November 16.
08:10 EDTOREXOrexigen announces allowance of new U.S. patent for Contrave
Orexigen Therapeutics announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the FDA.
November 17, 2014
14:02 EDTTLMTalisman Energy rises 1.6% to $5.78 following report on pipeline sale talks
Subscribe for More Information
14:01 EDTTLMTalisman in talks to sell Marcellus pipelines valued at over $1B, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use